<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="correction"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Adv Ther</journal-id><journal-id journal-id-type="iso-abbrev">Adv Ther</journal-id><journal-title-group><journal-title>Advances in Therapy</journal-title></journal-title-group><issn pub-type="ppub">0741-238X</issn><issn pub-type="epub">1865-8652</issn><publisher><publisher-name>Springer Healthcare</publisher-name><publisher-loc>Cheshire</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">28523624</article-id><article-id pub-id-type="pmc">5487865</article-id><article-id pub-id-type="publisher-id">543</article-id><article-id pub-id-type="doi">10.1007/s12325-017-0543-6</article-id><article-categories><subj-group subj-group-type="heading"><subject>Erratum</subject></subj-group></article-categories><title-group><article-title>Erratum to: Evaluation of the Short-Term Cost-Effectiveness of IDegLira Versus Continued Up-Titration of Insulin Glargine U100 in Patients with Type 2 Diabetes in the USA</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0001-5420-279X</contrib-id><name><surname>Hunt</surname><given-names>Barnaby</given-names></name><address><email>hunt@ossianconsulting.com</email></address><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Mocarski</surname><given-names>Michelle</given-names></name><xref ref-type="aff" rid="Aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Valentine</surname><given-names>William J.</given-names></name><xref ref-type="aff" rid="Aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Langer</surname><given-names>Jakob</given-names></name><xref ref-type="aff" rid="Aff3">3</xref></contrib><aff id="Aff1"><label>1</label>Ossian Health Economics and Communications, Basel, Switzerland </aff><aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="GRID">grid.452762.0</institution-id><institution/><institution>Novo Nordisk Inc., </institution></institution-wrap>Plainsboro, NJ USA </aff><aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="GRID">grid.425956.9</institution-id><institution/><institution>Novo Nordisk A/S, </institution></institution-wrap>S&#x000f8;borg, Denmark </aff></contrib-group><pub-date pub-type="epub"><day>18</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="pmc-release"><day>18</day><month>5</month><year>2017</year></pub-date><pub-date pub-type="ppub"><year>2017</year></pub-date><volume>34</volume><issue>6</issue><fpage>1500</fpage><lpage>1501</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2017</copyright-statement></permissions><related-article related-article-type="corrected-article" id="d29e91" ext-link-type="doi" xlink:href="10.1007/s12325-017-0502-2"/><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; Springer Healthcare Ltd. 2017</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1"><title>Erratum to: Adv Ther (2017) 34:954&#x02013;965 DOI 10.1007/s12325-017-0502-2</title><p id="Par1">In the original publication, Figure&#x000a0;3 was published incorrectly with errors. In Fig.&#x000a0;<xref rid="Fig3" ref-type="fig">3</xref>, the &#x0201c;Not defined*&#x0201d; labels should appear in the &#x02018;Insulin Glargine U100&#x02019; row of the table beneath the figure. In place of these the values &#x02018;41,530&#x02019; and &#x02018;57,642&#x02019;, respectively, should appear in the IDegLira row of the table beneath the figure. It has been corrected and the correct version is provided below.<fig id="Fig3"><label>Fig.&#x000a0;3</label><caption><p>Cost of control: patients with HbA1c &#x0003e;9.0% at baseline. $, 2015 US dollars; HbA1c, glycated hemoglobin. *Cost of control values cannot be calculated in the insulin glargine U100 arm for HbA1c &#x02264;6.5% without weight gain and HbA1c &#x02264;6.5% without confirmed hypoglycemia and weight gain, as no patients in the insulin glargine U100 arm achieved these treatment targets</p></caption><graphic xlink:href="12325_2017_543_Fig3_HTML" id="MO1"/></fig>
</p></sec></body><back><fn-group><fn><p>The online version of the original article can be found under doi:10.1007/s12325-017-0502-2.</p></fn></fn-group><ack><sec id="d29e220"><title>Open Access</title><p>This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.</p></sec></ack></back></article>